Dexycu

ApprovedSmall molecule

EEyePoint Pharmaceuticals, Inc.

Dexycu is one of 32 small molecule programs targeting Ocular pain. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular PainActive, not recruiting

CataractActive, not recruiting

Ocular PainPhase 3

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Floxin

WWim Janssens

Phase 3

1 2

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 3

Dexycu

EEyePoint Pharmaceuticals, Inc.

Approved

2 4

ISV-305

Sun Pharmaceutical Industries Limited

Phase 3

2 5

KPI-121

KKala Pharmaceuticals, Inc.

Phase 3

1 6

Zolymbus

AbbVie

Preclinical

—7

Neurontin

VViatris Specialty LLC

Preclinical

3 8

Kenalog

BBassett Healthcare

Preclinical

1 9

Bactroban

PPadagis LLC

Preclinical

1 10

Ceftin

PPhiladelphia Eye Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ocular pain2 trials

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

Withdrawn·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT05550350

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

Withdrawn·EEyePoint Pharmaceuticals, Inc.·Phase 3·NCT05550363

Cataract2 trials

"A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"

Completed·TThe Eye Institute of West Florida·Phase 4·NCT04781335·25 enrolled

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

Completed·OOcumension Therapeutics (Shanghai) Co., Ltd·Phase 4·NCT06497699·263 enrolled

Ocular Inflammation1 trial

Study of Dexycu in Treating Intraocular Inflammation

Completed·OOcumension Therapeutics (Shanghai) Co., Ltd·Phase 3·NCT06429306·285 enrolled

Dexamethasone1 trial

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

Completed·EEyePoint Pharmaceuticals, Inc.··NCT04290676·527 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Dexycu. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dexycu compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dexycu. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EyePoint Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEyePoint Pharmaceuticals, Inc.

Dexycu

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ocular pain2 trials

Cataract2 trials

Ocular Inflammation1 trial

Dexamethasone1 trial

References

Drug Info

Quick Facts

Related News